Tandem Diabetes Care (NSDQ:TNDM) posted Street-beating second-quarter sales and missed badly on earnings, but reinstated its earlier full-year 2020 guidance.

The San Diego-based company — maker of insulin pumps and other diabetes management devices — reported a loss of -$27.1 million or -0.45¢ per share, on sales of $109.2 million for the three months ended June 30, 2020, for a bottom-line loss of -17% compared with Q2 2019.

Get the full story on our sister site, MassDevice.